Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Becton Dickinson is putting its money where the supply chain is. The medical technology giant announced a $19 billion U.S. investment commitment — including $3 billion for domestic manufacturing expansion — as part of a government agreement to secure essential medical product supplies. In return, the company gets relief from potential Section 232 tariffs, provided it hits agreed milestones.
Becton Dickinson commits $19 billion to U.S. investment in deal to shield medical supplies from tariffs
Becton Dickinson (BD) is making a major bet on American manufacturing. The medical technology company announced a sweeping $19 billion U.S. investment plan spanning capital, operational, and supply-chain commitments — with $3 billion specifically earmarked for expanding manufacturing at strategic domestic sites.
The move comes as part of a formal agreement with the U.S. government aimed at strengthening the domestic supply of essential medical products. In exchange, BD will receive relief from future tariffs imposed under Section 232 on covered products and inputs — though that relief is contingent on the final scope of any tariff measures and the company meeting agreed-upon milestones.
By the Numbers:
Why it matters: This deal signals a broader push by the U.S. government to onshore critical medical supply chains, reducing dependence on foreign manufacturing for essential healthcare products. For the healthcare industry, it could mean greater supply stability — and sets a precedent for how future manufacturing policy deals may be structured.
